CAR-T Cell Therapy
20
10
12
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 20 trials
5%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (20)
INfections in Patients Treated With CAR-T
Pre-emptive Anakinra for Cytokine Event Reduction
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
Nutrition OUtReach In Systems of Healthcare
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients
A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
CAR T-CELL Therapy Educational Video Trial